Ticker: RXRX | Published: 2026-09-22
Insider buys, Tempus deal
RXRX is rallying moderately as stacked insider filings signal internal confidence and a newly disclosed non-exclusive RNA foundation model license to Tempus AI adds fresh monetization narrative on top of the ongoing AI drug platform story.
Sources: https://www.timothysykes.com/news/recursion-pharmaceuticals-inc-rxrx-news-2026_09_21/, https://www.marketscree